Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| IL17A mAb | Monospecific antibody | Immunological disease | Psoriasis,Axial spondyloarthritis SpA | Phase III | Global (except China) |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ILA-H5243 | Human | Human IL-17A / CTLA-8 Protein, His Tag (HPLC verified) |  |
|
|
| CEA-C092 | Human | ClinMax™ Human IL-17A / CTLA8 ELISA Kit | |||
| EP-140 | Human | IL-17A : IL-17RA [Biotinylated] Inhibitor Screening ELISA Kit | |||
| EP-139 | Human | IL-17A [Biotinylated] : IL-17RA Inhibitor Screening ELISA Kit | |||
| ILA-H5219 | Human | Human IL-17A / CTLA-8 Protein, premium grade |  |
|
|
| ILA-C52H7 | Canine | Canine IL-17A / CTLA-8 Protein, His Tag |  |
|
|
| ILA-C5249 | Cynomolgus | Cynomolgus IL-17A / CTLA-8 Protein, His Tag (MALS verified) |  |
|
|
| ILA-H82Q1 | Human | Biotinylated Human IL-17A / CTLA-8 Protein, His,Avitag™ |  |
|
|
| CT8-M5240 | Mouse | Mouse IL-17A / CTLA-8 Protein, His Tag (MALS verified) |  |
|
|
Loaded Biotinylated Human IL17A, His,Avitag (Cat. No. ILA-H82Q1) on SA Biosensor, can bind Human IL-17 RA, His Tag (Cat. No. ILA-H5222) with an affinity constant of 18.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Virulizin | Approved | Aptose | Virulizin, Virulizin-2 gamma | Mexico | Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | null | 1997-01-01 | Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Sarcoma, Kaposi; Melanoma; Uterine Cervical Neoplasms | Details | |
| Ixekizumab | LY-2439821 | Approved | Eli Lilly And Company | 拓咨, Taltz | EU | Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing | Eli Lilly And Company (Ireland) Ltd | 2016-03-22 | Non-radiographic axial spondyloarthritis; Depressive Disorder, Major; Pyoderma Gangrenosum; Spondylitis, Ankylosing; Spondylarthritis; Arthritis, Rheumatoid; Psoriasis; Arthritis, Psoriatic; Lichen Planus; Pemphigoid, Bullous; Pityriasis Rubra Pilaris; Plaque psoriasis | Details |
| Secukinumab | NVP-AIN-457; AIN-457; KB-03303A | Approved | Novartis Pharma Ag | Cosentyx, 可善挺 | United States | Arthritis, Juvenile; Arthritis, Psoriatic | Novartis Pharma Ag | 2014-12-26 | Uveitis; Polymyalgia Rheumatica; Graves Ophthalmopathy; Psoriasis; Hyperkeratosis, Epidermolytic; Tendinopathy; Arthritis, Psoriatic; Parapsoriasis; Lichen Planus; Asthma; Multiple Sclerosis; Hidradenitis Suppurativa; Arthritis; Inflammation; Ichthyosiform Erythroderma, Congenital; Plaque psoriasis; Dermatitis, Atopic; Gastroenteritis; Behcet Syndrome; Crohn Disease; Spondylarthropathies; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Necrobiosis Lipoidica; Non-alcoholic Fatty Liver Disease; Giant Cell Arteritis; Inflammatory Bowel Diseases; Alopecia Areata; Pyoderma Gangrenosum; Lupus Erythematosus, Discoid; Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing; Ichthyosis; Rotator Cuff Injuries; Arthritis, Rheumatoid; Spondylarthritis; Netherton Syndrome; Lupus Nephritis; Ichthyosis, Lamellar; Arthritis, Juvenile | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| UCB-0159 | UCB-0159 | Phase 1 Clinical | Ucb Sa | Autoimmune Diseases | Details |
| JNJ-63823539 | JNJ-63823539 | Phase 1 Clinical | Janssen Global Services Llc | Arthritis, Rheumatoid | Details |
| Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) | LZM－012; LZM012 | Phase 2 Clinical | Livzon Pharmaceutical Group Inc, Beijing Kanova Biomedical Technology Co Ltd | Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| IMU-935 | IMU-935 | Immunic Ag | Details | ||
| JNJ-61178104 | JNJ-61178104 | Phase 1 Clinical | Janssen Global Services Llc | Autoimmune Diseases | Details |
| Vunakizumab | SHR-1314 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Spondylarthritis; Autoimmune Diseases; Spondylitis, Ankylosing; Graves Ophthalmopathy; Lupus Nephritis; Psoriasis; Graves Disease; Arthritis, Psoriatic; Plaque psoriasis | Details |
| RO-7040547 | RG-7990; BIT-7201A; RO-7040547 | Genentech Inc, Novimmune Sa | Details | ||
| CJM-112 | CJM-112 | Phase 1 Clinical | Novartis Pharma Ag | Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Sclerosis; Multiple Myeloma; Psoriasis; Colorectal Neoplasms; Asthma; Hidradenitis Suppurativa; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai Junshi Biosciences) | JS005 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| CMAB-015 | CMAB015; CMAB-015 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Details | |
| Secukinumab biosimilar (Bio-Thera Solutions) | BAT-2306 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Plaque psoriasis | Details |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Depression; Anxiety; Hashimoto Disease; Coronavirus Disease 2019 (COVID-19); Healthy Aging; Inflammation | Details |
| ZL-1102 | ZL-1102; CB-001 | Phase 1 Clinical | Crescendo Biologics Ltd, Zai Lab (Shanghai) Co Ltd | Psoriasis | Details |
| Gumokimab | AK-111 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Spondylitis, Ankylosing; Spondylarthritis; Psoriasis; Plaque psoriasis | Details |
| Xeligekimab | GR-1501 | Phase 3 Clinical | Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd, Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd | Spondylarthritis; Lupus Nephritis; Psoriasis; Plaque psoriasis | Details |
| QX002N | QX-002N | Phase 2 Clinical | Qyuns Therapeutics Co Ltd | Spondylitis, Ankylosing | Details |
| HY-1770 | HY-1770; HY1770; HT-17; HT17 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |
| Sonelokimab | M-1095; ALX-0761; MSB-0010841 | Phase 2 Clinical | Ablynx Nv | Psoriasis; Hidradenitis Suppurativa | Details |
| DMT-310 | DMT-310 | Phase 2 Clinical | Dermata | Rosacea | Details |
| Izokibep | AFB-035; ABY-035; IMG-020; IMG020 | Phase 3 Clinical | Affibody Ab | Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa; Uveitis; Plaque psoriasis | Details |
| SSGJ-608 | 608; SSGJ-608 | Phase 3 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Psoriasis; Plaque psoriasis | Details |
This web search service is supported by Google Inc.
A-Z
